2023-10-02T09:51:11-05:00 2022-12-31 141442607 BST & CO CPAS LLP 10 BRITISH AMERICAN BLVD LATHAM NY 12110 990 2022-01-01 203654626 REGENERATIVE RESEARCH FOUNDATION REGE 5186948188 ONE DISCOVERY DRIVE RENSSELAER NY 12144 WILLIAM KAHN CPA CHAIR 5186948188 2023-09-19 1 WILLIAM KAHN CPA 999009999 0 JUDY A CAHEE P00281935 5184596700 2023-09-18 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z NEURAL STEM CELL INSTITUTE WILLIAM KAHN CPA ONE DISCOVERY DRIVE RENSSELAER NY 12144 7532149 0 X WWW.NEURALSCI.ORG X 2005 NY THE PRINCIPAL MISSION OF THE REGENERATIVE RESEARCH FOUNDATION IS TO DEVELOP REGENERATIVE STEM CELL THERAPIES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS): THE BRAIN, SPINAL CORD, AND RETINA. 8 7 43 15 0 0 4650213 6469338 281050 577571 163 204 168023 485036 5099449 7532149 0 0 0 0 2280951 2753191 0 0 0 2330238 3096056 4611189 5849247 488260 1682902 4518761 5981949 2179152 1959438 2339609 4022511 THE PRINCIPAL MISSION OF THE REGENERATIVE RESEARCH FOUNDATION IS TO DEVELOP REGENERATIVE STEM CELL THERAPIES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS): THE BRAIN, SPINAL CORD, AND RETINA. 0 0 1683832 327571 FISCAL YEAR 2022 SAW THE REGENERATIVE RESEARCH FOUNDATION'S OPERATIONS RETURN TO A MORE NORMAL LEVEL OF ACTIVITY. THE LABORATORIES WERE FULLY STAFFED, AND THE FOUNDATION RENEWED ITS COMMITMENT TO PURSUING ITS MISSION TO DEVELOP POTENTIAL THERAPIES FOR TREATMENT FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM. FOUNDATION RESEARCHERS PUBLISHED A TOTAL OF SEVEN ARTICLES REPORTING THE RESULTS OF THEIR INVESTIGATIONS IN SEVERAL PROMINENT SCIENTIFIC JOURNALS. THE TOPICS INCLUDED NEURODEGENERATIVE, EYE AND ALZHEIMER'S DISEASE. THESE ARTICLES ARE MADE AVAILABLE FREELY TO THE SCIENTIFIC COMMUNITY AND THE GENERAL PUBLIC THROUGH THE NATIONAL INSTITUTES OF HEALTH PUB-MED CENTRAL PUBLICATION RETRIEVAL SYSTEM. INVESTIGATORS AT THE FOUNDATION WERE ABLE TO SECURE 10 NEW RESEARCH GRANTS TO CONTINUE AND EXPAND THE STEM CELL RESEARCH PROGRAMS. 1176261 250000 THE FOUNDATION INITIATED ITS PLANNED CLINICAL TRIAL DURING FISCAL YEAR 2022 AFTER SURMOUNTING NUMEROUS OBSTACLES INCLUDING THE PANDEMIC AND RETINAL STEM CELL PRODUCT MANUFACTURING DELAYS. THREE STUDY SUBJECTS RECEIVED THE RETINAL PIGMENT EPITHELIUM STEM CELL REPLACEMENT THERAPY DEVELOPED BY THE FOUNDATION. THE RESULTS OF THIS THERAPEUTIC INTERVENTION FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION ARE PROMISING. THE FOUNDATION HOPES TO EXPAND THESE CLINICAL STUDIES WITH ITS BIOTECHNOLOGY PARTNERSHIP AND MAKE THE THERAPY READILY AVAILABLE TO THOSE SUFFERING FROM AMD. 2148323 THE ALZHEIMER'S AND RELATED DEMENTIA RESEARCH PROGRAM CONTINUED ITS INVESTIGATIONS INTO THE CAUSES AND TREATMENT OF THESE DISEASES. THE FOUNDATION ALSO EXPANDED ITS DEMENTIA PROGRAM BY ESTABLISHING SEVERAL COLLABORATIVE ARRANGEMENTS INCLUDING A PROJECT INVOLVING FIVE COLLABORATIVE LABORATORIES AT DIFFERENT ACADEMIC INSTITUTIONS. SUPPORT FOR THESE ENDEAVORS WAS PROVIDED BY THE NATIONAL INSTITUTES OF HEALTH AND VARIOUS PUBLIC CHARITIES. IN ADDITION, THE FOUNDATION ENTERED INTO AN AGREEMENT WITH A BIOTECHNOLOGY COMPANY TO RESEARCH A POTENTIAL NEURODEGENERATIVE DISEASE TREATMENT. 5008416 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 1 43 1 0 0 0 0 0 0 0 0 0 0 0 0 X 8 7 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 1 1 NY X THOMAS J IRWIN 5186948189 ONE DISCOVERY DRIVE RENSSELAER NY 12144 WILLIAM KAHN CPA CHAIR 5.00 X X 0 0 0 JEFFREY H STERN MD PHD DIRECTOR FOR TRANSLATIONAL 30.00 X X 47400 0 486 JOHN WALSH DIRECTOR 2.00 X 0 0 0 VITO GRASSO MPA CAE DIRECTOR 1.00 X 0 0 0 DAVID O CARPENTER MD DIRECTOR 1.00 X 0 0 0 DAWN ABBUHL DIRECTOR 1.00 X 0 0 0 ROBERT CATALANO MD DIRECTOR 1.00 X 0 0 0 AMY G KLANN PHD JD DIRECTOR 1.00 X 0 0 0 SALLY TEMPLE-STERN PHD SCIENTIFIC & EXECUTIVE DIR 70.00 X 174326 0 8727 CAITLIN HILL PRINCIPAL INVESTIGATOR 50.00 X 129400 0 6478 THOMAS IRWIN ADMINISTRATIVE DIRECTOR 36.00 X 101236 0 11309 452362 0 27000 3 0 1 0 0 5578681 890657 6469338 SPONSORED RESEARCH 541700 577571 577571 577571 204 204 27604 27604 NEURACELL INCOME 541700 457432 457432 457432 7532149 577571 0 485240 230939 230939 2069236 1692703 376533 62062 51162 10900 224739 188894 35845 166215 139967 26248 148337 145832 2505 20518 20518 169317 113443 55874 26562 8123 18439 21165 2330 18835 351707 339891 11816 37778 33245 4533 16145 8763 7382 54711 54711 27919 27919 RESEARCH SUBCONTRACTS 1042391 1042391 LABORATORY CHARGES 1018935 846304 172631 EQUIP. REPAIR & MAINT. 106477 105510 967 BAD DEBT 37571 0 37571 16523 4208 12315 5849247 5008416 840831 0 282539 678162 1382853 1931726 939297 1693916 92222 203006 139782 120161 3709609 3616608 119505 93001 1562563 1261977 4518761 5981949 605389 711170 1573763 1248268 2179152 1959438 X 1454706 3024854 884903 997657 2339609 4022511 4518761 5981949 1682902 0 X 0 1 X 1 1 1 X 3144770 3109318 2767480 4650213 6469338 20141119 3144770 3109318 2767480 4650213 6469338 20141119 2382220 17758899 34305 26048 12077 7275 27808 107513 69761 112749 99146 160911 457432 899999 21148631 1837665 0.83970 0.86560 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2018 AMOUNT: $ 4,363. 2020 AMOUNT: $ 4,335. NEURACELL INCOME - 2018 AMOUNT: $ 65,398. 2019 AMOUNT: $ 112,749. 2020 AMOUNT: $ 94,811. 2021 AMOUNT: $ 160,911. 2022 AMOUNT: $ 457,432. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 24699 23013 1686 3684910 3593595 91315 93001 OTHER RECEIVABLE 35635 ROU ASSET - OPERATING LEASE 1226342 1261977 OPERATING LEASE LIABILITY 1248268 1248268 X 7532149 0 7532149 0 7532149 5849247 0 5849247 0 5849247 PART X, LINE 2: THE FOUNDATION FILES FORM 990 ANNUALLY WITH THE INTERNAL REVENUE SERVICE. WHEN ANNUAL RETURNS ARE FILED, SOME TAX POSITIONS TAKEN ARE HIGHLY CERTAIN TO BE SUSTAINED UPON EXAMINATION BY THE TAXING AUTHORITIES, WHILE OTHER TAX POSITIONS ARE SUBJECT TO UNCERTAINTY ABOUT THE TECHNICAL MERITS OF THE POSITION OR AMOUNT OF THE POSITION'S TAX BENEFIT THAT WOULD ULTIMATELY BE SUSTAINED. MANAGEMENT EVALUATED THE FOUNDATION'S TAX POSITIONS, INCLUDING INTEREST AND PENALTIES ATTRIBUTABLE THERETO, AND CONCLUDED THAT THE FOUNDATION HAD TAKEN NO TAX POSITION THAT REQUIRED ADJUSTMENT IN ITS FINANCIAL STATEMENTS AS OF DECEMBER 31, 2022 OR 2021. X X 0 0 0 0 0 0 0 0 0 SALLY TEMPLE-STERN PHD SCIENTIFIC & EXECUTIVE DIR 174326 0 0 0 0 0 6962 0 1765 0 183053 0 0 0 SALLY TEMPLE-STERN SEE PART V 183053 SEE PART V 0 JEFFREY H STERN SEE PART V 47886 SEE PART V 0 SCHEDULE L, PART IV, LINE 1, COLUMN B: SALLY TEMPLE-STERN IS THE EXECUTIVE AND SCIENTIFIC DIRECTOR OF THE ORGANIZATION AND ALSO HAS A FAMILY RELATIONSHIP WITH A CURRENT BOARD MEMBER. SCHEDULE L, PART IV, LINE 1, COLUMN D: SALLY TEMPLE-STERN IS COMPENSATED FOR SERVICES PERFORMED AS THE EXECUTIVE AND SCIENTIFIC DIRECTOR OF THE ORGANIZATION. HER COMPENSATION IS DETERMINED BY THE GOVERNING BOARD AS DISCLOSED IN SCHEDULE O. SCHEDULE L, PART IV, LINE 2, COLUMN B: JEFFREY H. STERN IS THE TRANSLATIONAL RESEARCH DIRECTOR OF THE ORGANIZATION AND ALSO HAS A FAMILY RELATIONSHIP WITH A CURRENT OFFICER. SCHEDULE L, PART IV, LINE 2, COLUMN D: JEFFREY H. STERN IS COMPENSATED FOR SERVICES PERFORMED AS THE TRANSLATIONAL RESEARCH DIRECTOR OF THE ORGANIZATION. HIS COMPENSATION IS DETERMINED BY THE GOVERNING BOARD AS DISCLOSED IN SCHEDULE O. FORM 990, PART VI, SECTION A, LINE 2 DR. JEFFREY STERN AND DR. SALLY TEMPLE-STERN HAVE A FAMILY AND BUSINESS RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE ORGANIZATION'S FORM 990 WAS DISTRIBUTED TO AND REVIEWED BY THE BOARD PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C EVERY BOARD MEMBER IS PROVIDED A COPY OF THE CONFLICT OF INTEREST POLICY AND ALL RELATIONSHIPS INVOLVING AN APPARENT OR POTENTIAL CONFLICT OF INTEREST ARE DISCUSSED BY THE BOARD IN ADVANCE OF THE FOUNDATION ENTERING INTO ANY TRANSACTION OR RELATIONSHIP. THE BOARD ALSO REVIEWS ITS CONFLICT OF INTEREST POLICY ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION OF ALL EMPLOYEES INCLUDING THE FOUNDATION'S EXECUTIVE DIRECTOR AND OTHER INDIVIDUALS IS REVIEWED AND APPROVED PERIODICALLY BY THE GOVERNING BOARD. THE BOARD CONSIDERS BOTH COMPARATIVE POSITIONS AND GEOGRAPHIC FACTORS WHEN MAKING ITS DECISION. FORM 990, PART VI, SECTION C, LINE 19 ALL FOUNDATION GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST EITHER IN PERSON, BY TELEPHONE OR EMAIL.